% | $
Quotes you view appear here for quick access.

iCAD, Inc. Message Board

  • culleraa culleraa Feb 20, 2013 8:06 AM Flag

    Mix and momentum

    I guess many were betting on higher therapy sales.. these were down sequentially by 1.3 m which needs explaining. Others were betting on higher sequential CAD sales, which indeed happened. Overall, not bad as better margin. Key is what happens next now that there is a better CMS payment. Will that have an effect in q1? The Deerfield "hung, drawn and quartered "financing keeps the show going for many years (at a huge dilution, interest and revenue cost). No rush in or out...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • mikejoneswhatmikejones mikejoneswhatmikejones Feb 20, 2013 11:50 AM Flag

      Huge dilution, interest and revenue cost? The revenue hurts, but only as revenues increase. With gross margin somewhere in the high 60s shareholders shouldn't be complaining too much about that. I don't know that I would call 4.5% dilution and 5.75% interest huge, but I suppose that is a personal judgement.

      What you need to be worried about is management getting sloppy with increasing revenues. They've made pretty strong cuts over the last few years out of necessity. Let's see if cost control continues to remain an item of focus.

    • Should add that the therapy dollar is worth more than the cad dollar! In theory, icad is doing "robotic diagnostics", but the market does not value this like isrg! Since icad didn't develop a sustainable business model it is not surprising. they still could, but don't hold your breath...

3.350.00(0.00%)Oct 9 3:59 PMEDT